4D Molecular Therapeutics (FDMT) - Guggenheim 3rd Annual Healthcare Innovation Conference - 4D MOLECULAR THERAPEUTICS INC

Explicit Guidance:

• Topline Data Timelines: Expected Q2 2027 for the "Forefront One" (North American) trial; expected back half of 2027 for the "Forefront Two" (Global) trial.
• Cash Runway: Current cash and cash equivalents of $430 million (as of end of Q2) are projected to fund operations into the second half of 2028, excluding future commercialization spend contingent on positive Forefront One data.
• Target Product Profile: Aiming for a single-dose, intravitreal injection providing lifelong continuous disease control (backbone therapy) with potential for injection freedom.

Business-Segment Outlook:

• Lead Asset (4D150): Positioned as a continuous backbone therapy for wet AMD (addressing a $16 billion global market) to replace episodic bolus injections.
• Patient Targeting Strategy: Initial commercial volume expected from patients with high disease burden (motivated for alternatives) in the first 6–9 months post-launch; broadening to moderate and lower burden patients once safety and reimbursement are established.
• Additional Indications: Clinical trials for Diabetic Macular Edema (DME) initiated two months prior to the conference; expanded interest in the broader modality for diabetic eye disease.
• Commercial Infrastructure: Committing to significant post-data commercialization spending (buy-and-bill model alignment with current retina practice operations) contingent on Phase 3 success.

Market and Competitive Outlook:

• Treatment Paradigm Shift: Aiming to move the market from episodic "bolus" anti-VEGF treatments to a chronic, "always-on" therapy to eliminate the "continuous control gap" caused by real-world patient non-adherence and undertreatment.
• Competitive Positioning: Differentiates from incremental durability improvements (e.g., extended Q8, Q10, Q12 dosing) by offering a single-dose solution capable of sustained suppression; claims potential for >87% reduction in treatment burden (based on Phase 1/2 data) and ~66% injection-free rate.
• Adoption Barriers & Enablers: Relies on fitting into existing clinical workflows (intravitreal injection vs. surgical sub-retinal delivery) and utilizing familiar reimbursement models to drive adoption by physicians, patients, and payers.

Macro / Industry Outlook:

• Regulatory Environment: Phase 3 designs (Forefront Two) include patients previously treated for up to six months to satisfy specific European regulatory requirements.
• Reimbursement Strategy: Anticipates seamless integration into the standard "buy and bill" model used by retina practices for current anti-VEGF therapies.

Strategic Initiatives:

• Clinical Execution: Two Phase 3 programs (Forefront One: North American; Forefront Two: Global) with non-inferiority designs comparing 4D150 to aflibercept (Eylea). Enrollment for Forefront One completed four months ahead of schedule.
• Technology Leverage: Utilizing proprietary R100 capsid (Nobel Prize-derived directed evolution technology) to enable targeted intravitreal delivery with low doses and favorable safety profiles (no severe inflammatory events observed in Phase 1/2).
• Commercial Readiness: Preparing for post-data commercialization spending, specifically timing capital allocation decisions for commercial infrastructure based on the outcome of the Forefront One trial.

Risks and Headwinds to Outlook:

• Clinical Trial Risks: Potential for catastrophic vision loss in the placebo arm due to extraneous conditions; mitigation involves strict patient selection (VEGF responsiveness, capped CST) and aggressive early retreatment protocols to protect primary endpoints (non-inferiority of vision).
• Real-World Efficacy: Future treatment burden reduction metrics (currently ~87% in Phase 1/2) may vary in the commercial setting; management prioritizes hitting the primary vision endpoint over maintaining exact burden reduction rates seen in early trials.
• Reimbursement & Safety: Future commercial adoption is contingent on real-world safety establishment and payer acceptance of the new modality.

Management Tone on the Future:

• Confidence Level: High confidence in the "backbone therapy" concept and the alignment of the product with the chronic biology of the disease.
• Strategic Stance: Management views their approach as a fundamental shift rather than an incremental improvement, expressing strong excitement about the potential to preserve vision long-term and eliminate the "pulsating" nature of fluid control associated with current bolus therapies.
• Caveats: Tone acknowledges that broader patient population adoption will take time post-launch, contingent on the establishment of real-world safety and payer confidence.

Miscellaneous:

• Market Size Context: Wet AMD/anti-VEGF category valued at approximately $16 billion globally with steady growth.
• Phase 1/2 Data Reference: PRISM study data (2-year results) cited as a leading indicator, showing 1.66 supplemental injections over two years (vs. 12 expected with standard of care) and 66% of patients becoming supplement-free.